×
About 7,564 results

ALLMedicine™ Gastrointestinal Stromal Tumors Center

Research & Reviews  3,597 results

SDHC Methylation Pattern in Patients With Carney Triad.
https://doi.org/10.1097/PAI.0000000000000920
Applied Immunohistochemistry & Molecular Morphology : AIMM; Daumova M, Svajdler M et. al.

Feb 24th, 2021 - Carney triad is a multitumor syndrome affecting almost exclusively young women in a nonfamilial setting, which manifests by multifocal gastric gastrointestinal stromal tumors, paragangliomas, and pulmonary chondroma. The Carney triad-associated tu...

Succinate dehydrogenase deficient gastrointestinal stromal tumor in a three month old b...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897371
Diagnostic Pathology; Lv BB, Li JM et. al.

Feb 22nd, 2021 - Succinate dehydrogenase deficient gastrointestinal stromal tumors (SDH-deficient GISTs), which lack KIT or PDGFRA mutations demonstrate unique clinical and pathological features, and they respond poorly to standard targeted therapy. We herein pres...

A case report of duodenal perforation caused by imatinib mesylate during adjuvant treat...
https://doi.org/10.5414/CP203808
International Journal of Clinical Pharmacology and Therap... Liao MJ, Wu YQ et. al.

Feb 19th, 2021 - Imatinib, a tyrosine kinase inhibitor, is frequently used to treat unresectable or metastatic gastrointestinal stromal tumors. The application of this medication is considered an adjuvant treatment of gastrointestinal stromal tumors. It can reduce...

Gut microbiota of patients with different subtypes of gastric cancer and gastrointestin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888145
Gut Pathogens; Sarhadi V, Mathew B et. al.

Feb 18th, 2021 - Gastric adenocarcinoma is associated with H. pylori infection and inflammation that can result in the dysbiosis of gastric microbiota. The association of intestinal microbiota with gastric adenocarcinoma subtypes or with gastric gastrointestinal s...

Radical resection versus local excision for low rectal gastrointestinal stromal tumor: ...
https://doi.org/10.1016/j.ejso.2021.01.027
European Journal of Surgical Oncology : the Journal of Th... Wang T, Zhao Y et. al.

Feb 14th, 2021 - The surgical approaches and resection extent for rectal gastrointestinal stromal tumors (GISTs) are controversial due to the low incidence of this disease. A multicenter retrospective cohort study was conducted to compare the postoperative and onc...

see more →

Guidelines  11 results

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.

Dec 25th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, t...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy095/5004450
Casali, P. G.

May 27th, 2018 - Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year. This only covers clinically relevant GISTs, since, if investigated, a much higher number of lesions ≤ 1 cm in diameter (mic.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal str...
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Soc... Bellera CA, Penel N et. al.

Jul 29th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  3,789 results

SDHC Methylation Pattern in Patients With Carney Triad.
https://doi.org/10.1097/PAI.0000000000000920
Applied Immunohistochemistry & Molecular Morphology : AIMM; Daumova M, Svajdler M et. al.

Feb 24th, 2021 - Carney triad is a multitumor syndrome affecting almost exclusively young women in a nonfamilial setting, which manifests by multifocal gastric gastrointestinal stromal tumors, paragangliomas, and pulmonary chondroma. The Carney triad-associated tu...

Succinate dehydrogenase deficient gastrointestinal stromal tumor in a three month old b...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897371
Diagnostic Pathology; Lv BB, Li JM et. al.

Feb 22nd, 2021 - Succinate dehydrogenase deficient gastrointestinal stromal tumors (SDH-deficient GISTs), which lack KIT or PDGFRA mutations demonstrate unique clinical and pathological features, and they respond poorly to standard targeted therapy. We herein pres...

A case report of duodenal perforation caused by imatinib mesylate during adjuvant treat...
https://doi.org/10.5414/CP203808
International Journal of Clinical Pharmacology and Therap... Liao MJ, Wu YQ et. al.

Feb 19th, 2021 - Imatinib, a tyrosine kinase inhibitor, is frequently used to treat unresectable or metastatic gastrointestinal stromal tumors. The application of this medication is considered an adjuvant treatment of gastrointestinal stromal tumors. It can reduce...

Gut microbiota of patients with different subtypes of gastric cancer and gastrointestin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888145
Gut Pathogens; Sarhadi V, Mathew B et. al.

Feb 18th, 2021 - Gastric adenocarcinoma is associated with H. pylori infection and inflammation that can result in the dysbiosis of gastric microbiota. The association of intestinal microbiota with gastric adenocarcinoma subtypes or with gastric gastrointestinal s...

Radical resection versus local excision for low rectal gastrointestinal stromal tumor: ...
https://doi.org/10.1016/j.ejso.2021.01.027
European Journal of Surgical Oncology : the Journal of Th... Wang T, Zhao Y et. al.

Feb 14th, 2021 - The surgical approaches and resection extent for rectal gastrointestinal stromal tumors (GISTs) are controversial due to the low incidence of this disease. A multicenter retrospective cohort study was conducted to compare the postoperative and onc...

see more →

News  161 results

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.staging.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

Ripretinib Extends Survival When All Else Fails in Advanced GIST
https://www.medscape.com/viewarticle/933412

Jul 5th, 2020 - NEW YORK (Reuters Health) - Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the IN...

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

see more →

Patient Education  4 results see all →